Cholrem Pty Ltd is a specialty bio-pharmaceutical company established in 2018 to explore the possibility of Cyclodextrin becoming a treatment for cardiovascular disease.

Leveraging advanced proprietary technologies, Cholrem set out to develop first-in-class drugs to treat and remove harmful cholesterol from the vascular system.

Cholrem Pty Ltd conducted world first trials using HP-B-CD with patients suffering advanced cardiovascular disease. The results showed substantial plaque reduction within 4 weeks of treatment.

Advancements in our development of Cyclodextrin resulted in our creation of CAVADEX®, a proprietary Cyclodextrin that is shown to have enhanced cholesterol transport and removal from the vascular system without any adverse side effects.

Visit our American company website